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Abstract
Before the EU General Data Protection Regulation entered into force in May 2018, we witnessed an intense struggle of
actors associated with data-dependent fields of science, in particular health-related academia and biobanks striving for
legal derogations for data reuse in research. These actors engaged in a similar line of argument and formed issue alliances
to pool their collective power. Using descriptive coding followed by an interpretive analysis, this article investigates the
argumentative repertoire of these actors and embeds the analysis in ethical debates on data sharing and biobank-related
data governance. We observe efforts to perform a paradigmatic shift of the discourse around the General Data
Protection Regulation-implementation away from ‘protecting data’ as key concern to ‘protecting health’ of individuals
and societies at large. Instead of data protection, the key risks stressed by health researchers became potential obstacles
to research. In line, exchange of information with data subjects is not a key concern in the arguments of biobank-related
actors and it is assumed that patients want ‘their’ data to be used. We interpret these narratives as a ‘reaction’ to
potential restrictions for data reuse and in line with a broader trend towards Big Data science, as the very idea of
biobanking is conceptualized around long-term use of readily prepared data. We conclude that a sustainable implemen-
tation of biobanks needs not only to comply with the General Data Protection Regulation, but must proactively
re-imagine its relation to citizens and data subjects in order to account for the various ways that science gets entangled
with society.
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Introduction
In December 2015, the Trialogue of the European
Parliament, the European Commission (EC) and the
Council of Europe came to an agreement on the ﬁnal
version of the EU General Data Protection Regulation
(GDPR). The GDPR was then adopted by the Council
and the Parliament; it was ﬁnally published on 4 May
2016 and has been applicable in all member states since
May 2018 (EC, 2016). This is the preliminary endpoint
of a long and controversial policy process, which
started much earlier and went through major phases
of renegotiation including many more actors.
This paper explores a speciﬁc part of this policy pro-
cess, focusing on the interventions of actors associated
with data-dependent ﬁelds of health-related sciences,
more speciﬁcally biobanks, in the drafting of the
GDPR. Between 2012 and 2015, these actors called
for legal derogations for research that would allow sci-
entists to reuse human-related data based on a one-time
informed consent by donors. Such derogations were
suggested by the EC in 2012, later opposed by, e.g.,
the European Parliament, and ﬁnally included in the
GDPR. We analyse how interventions by actors
from data-dependent ﬁelds of science to the GDPR
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negotiations (expressed in public documents such as
policy briefs and open letters) aim for shifting the dis-
course from its key topic ‘data protection’, to a para-
digmatic focus on ‘protecting the health’ of individuals
and societies at large. We interpret this eﬀort as part of
an epistemic transition, where Big Data approaches are
increasingly framed as necessary innovative modes for
knowledge generation to serve the public good.
Analysing such moments of controversy between diﬀer-
ent actors then opens a window to better understand
the new role data-intensive sciences are starting to play,
how this challenges the very act of data donation, but
also of protection of donors, how data-subjects arise as
a new category of actors and shows us the complex
balancing acts between individual rights and the prom-
ise of collective beneﬁts.
Big Data poses technical challenges not only to
research but also to privacy management and research
organization more generally (Lehtiniemi and
Kortesniemi, 2017). Large-scale health databases
cannot be understood simply as up-scaled version of
previous collections of data; they generally bring
together much larger and more diverse sets of informa-
tion (and biological materials). This, as we will argue,
calls for being attentive to not simply buying into pre-
existing ethical, social and legal perspectives but to
opening up and being open to new understandings
and approaches (e.g. Prainsack and Buyx, 2016).
Novel technologies enable the automated and quasi-
autonomous collection and analysis of data across dif-
ferent technological domains, connecting diﬀerent data
collections more easily, while storage technologies
allow these data to be kept for undeﬁned lengths of
time. Some scholars highlight that Big Data conﬂicts
in important ways with individual privacy rights (Kulk
and Van Loenen, 2012) because the subjects of the data
are said to no longer be aware of the extent to which
data are being collected and used (Mittelstadt and
Floridi, 2016). Anonymization is also diﬃcult in regard
to large data collections as (for example genetic) data
may aﬀect not only the privacy rights of individuals
but also the rights of whole groups for ethnic or geo-
graphic reasons (Lunshof et al., 2008). Furthermore, Big
Data approaches ‘challenge established epistemologies
across the sciences’ bringing about ‘new forms of empiri-
cism that declare ‘‘the end of theory’’, the creation of
data-driven rather than knowledge-driven science’
(Kitchin, 2014: 1). Researchers increasingly face novel
demands for data management and protection as well
as for informed consent, which has reinvigorated debates
about the relationship of science and society as well as
about the modes of inclusion of research subjects more
speciﬁcally (Starkbaum, 2018).
With the backdrop of these changes, it is not aston-
ishing that actors from data-dependent ﬁelds of science
were very active in negotiating the GDPR. In particu-
lar, actors associated with publicly funded European
biobanks strived for forming a ‘discourse coalition’
(Hajer, 2009). Such a discourse coalition is made up
of an ‘ensemble of particular storylines (. . .), the
actors who employ them, and the practices through
which the discourse involved exerts its power’ (Hajer,
2009: 60), and very often is issue speciﬁc. We concep-
tualize the aggregation of such formations of actors as
a ‘policy network’, which shifts our attention to diﬀer-
ent types of (political) power relations (Marin and
Mayntz, 1991). Accordingly, actors with shared
system-related interests would create an alliance
around a speciﬁc issue that is often not formalized
but rather materialized through shared discourses and
narratives. Related approaches point to epistemic com-
munities that build on shared expertise to inform policy
(Zito, 2017), or they emphasize the eﬀorts of framing
the issues at stake in order to draw our attention to how
interest groups ‘strategically highlight some aspects
(. . .) while neglecting others in order to direct collective
attention to their preferred policy option’ (Klu¨ver et al.,
2015: 495).
However, in this paper, we will not focus on the
actual policy impact of the issue alliance of health-
related actors in the broader struggle over the GDPR,
as this is hardly possible in such a complex negotiation
process. Nor will we analyse the ‘assembly’ of actors as
such. Rather, we reﬂect the argumentative repertories
linked to these interventions and how they can be inter-
preted as an attempt to discursively shift the struggle
over the use of personal data in research. We will thus
start with reﬂecting on the governance of health-data
infrastructures, more speciﬁcally looking into the emer-
gence of (European) health-data infrastructures (fol-
lowing section). This is followed by a genealogy of
approaches to biobank governance (subsequent sec-
tion). Building on this, we will then in fourth section
outline how the negotiations over the GDPR opened
up a space of intervention for diﬀerent actors. Finally,
we will focus in on narratives performed through public
documents which are central to the formation of the
aforementioned issue alliance (ﬁnal section).
The analysis is based on a selection of 27 documents
that were collected based on desktop research and
snowballing techniques. We sampled public documents
that fulﬁl the following criteria: (1) they explicitly
address the GDPR in relation to biobanking or bio-
bank-like research (e.g. cohort studies), (2) they are
authored by actors associated with data-dependent
ﬁelds of science and (3) the authors are aﬃliated with
an entity that is publicly funded (e.g. universities and
associations of academics) or are part of the not-
for-proﬁt sector (e.g. patient organizations). Out of
the 27 analysed documents, only one document is
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authored by a single institution, 17 of them by institu-
tionalized associations and assemblies, and nine by
temporal assemblies of actors, sometimes including
entities from both science and patient organizations
(e.g. Wellcome Trust et al., 2014). Please see Table 1
in Supplementary material for further details.
The documents were, ﬁrst, coded following a
descriptive approach (Saldan˜a, 2016), in order to
inductively provide an overview on key topics. In a
second step, the coded documents were analysed fol-
lowing an interpretive approach to research, framing
these as ‘situationally embedded creations’ (Wolﬀ,
2007: 285) produced for particular purposes and audi-
ences. We thus reﬂected not only the content of the
documents but also their position and the context for
which they were produced: as elements of a ‘struggle
over meaning’ (Braun, 2015) that display perspectives
and intentions of its authors (Hammersley and
Atkinson, 2007). These documents are in this sense an
important source as they are both accounts of speciﬁc
values and work performed by an actor and accounts
for organizational activities, i.e., of how to formally
intervene in such debates. We then elaborated key nar-
ratives and a greater ‘red threat’ across the 27 docu-
ments which provide the empirical basis for this article.
We ﬁnally discuss how the formation of a discourse
coalition, its focus on potential beneﬁts, and the ways
how patients and citizens are imagined, can be under-
stood as a ‘reaction’ to potential restrictions for data
reuse, as the very idea of biobanking is conceptualized
around long-term use of readily prepared data. All this
relates to eﬀorts for performing a paradigmatic shift of
the GDPR-implementation-discourse away from ‘pro-
tecting data’ to ‘protecting health’ of individuals and
societies at large. While the exchange of information
with data subjects is no key issue in the narratives, we
argue that a sustainable implementation of biobanks
needs not only to comply with the current legal
framework, but must proactively re-imagine and re-
conceptualize its relation to citizens and data subjects.
Health-data and biobank infrastructures
At the time of writing this article, we are witnessing
multiple eﬀorts to establish (health) data platforms
for research, such as Electronic Health Record systems
or biobank infrastructures, and these infrastructures
seek preferably wide access to and options for the
reuse of data. The European e-Health Action Plan
(EC, 2012a), for example, targets (digital) data collec-
tion and new information and communication technol-
ogies as tools to provide cost-eﬃcient and high-quality
medical care and treatment across Europe. The
Digital Single Market Strategy for Europe (EC, 2015)
also aims at harmonizing the health sector.
Simultaneously, private health-data platforms are
emerging, such as direct-to-consumer genetic testing
or private health management (Swan, 2013). These
health-related activities have raised a critical debate in
regard to issues in particular data privacy, research
ethics, and commercialization.
This article speciﬁcally examines the actors asso-
ciated with publically funded human biobanks (and
their EU infrastructure). These types of biobanks are
typically situated at single locations (e.g. a hospital or
university). The banks collect, store, and process
human data (e.g. blood or tissue), clinical data (e.g.
heartbeats) and lifestyle data (e.g. smoking habits) for
research purposes. In most cases, human bodily mater-
ial is kept deep-frozen or paraﬃn-ﬁxed, and data may
be derived from patient groups or larger segments of
populations. The sample sizes of biobanks can range
from data on a few hundred donors to data collected
from a million or more donors. Countless biobanks
exist across Europe and worldwide.
The trend for bigger data in omics research led to the
ongoing integration of European biobanks around the
turn of the last millennium (Rial-Sebbag and Cambon-
Thomsen, 2015). The Biobanking and Biomolecular
Resources Research Infrastructure – European
Research Infrastructure Consortium (BBMRI-ERIC),
a major EU biomedical infrastructure, was gradually
developed over the course of the last two decades and
inaugurated in 2013. Its declared aim is to improve
cooperation between biobanks and other partners
(e.g. from policy and industry) and thus promote sci-
entiﬁc research across Europe. In 2015, more than 500
European biobanks were part of this EU infrastructure
(Starkbaum, 2018). However, biobanks also raised a
number of socio-ethical and legal questions, many of
them related to data privacy.
Therefore, it is not surprising that biobanks and the
BBMRI-ERIC infrastructure felt quite fundamentally
aﬀected by the GDPR. Biobanks not only systematic-
ally collect large amounts of data from patients or citi-
zens; beyond that role, their declared aim is to be able
to use these data for multiple yet currently unknown
research purposes. We encounter a ﬁeld of ‘data-driven
innovation’ (Curley and Salmelin, 2018) where diﬀerent
types of data are framed not only as valuable but as key
elements of biomedical knowledge generation and thus
become a highly politicized resource.
Supporters of a strict data protective framework
aimed precisely at restricting data reuse based on a
one-time informed consent (i.e. prohibiting broad or
blanket consent). This challenged the core reasons
why biobanks were created in the ﬁrst place as well as
their very epistemology. In response, various actors
connected to biobanks actively engaged in negotiations
over the GDPR. However, before shedding light on
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some of these interventions, it is essential to reﬂect on
earlier debates on biobank governance because many
issues addressed in the GDPR-related interventions of
biobank-associated actors have a quite long pre-
history.
Wider debates around data governance
of biobanks
Regarding questions of governance, the ﬁeld of bio-
banks experienced – and still experiences – intense eth-
ical, social and legal debates on issues such as
ownership, beneﬁt sharing, informed consent, and
data privacy (Rial-Sebbag and Cambon-Thomsen,
2015). To understand how these debates emerged and
developed, it is noteworthy to look a few decades back
to the wider ﬁeld of biotechnology. With the rise of the
Human Genome Project in the 1990s, the role of gen-
etic data with regard to individual autonomy rights was
increasingly discussed. The term genetic privacy was
promoted by scholars to capture the novel challenges
associated with genetic data (data that contains simul-
taneous information about individuals and collectives)
(Lunshof et al., 2008). The leading assumption behind
this term was that genetic information is diﬀerent from
other types of information and therefore requires spe-
ciﬁc policies: thus, speciﬁc protection against the misuse
of personal genetic data was claimed. However, restric-
tions to data usage challenge biobanks as the very idea
of collecting (human) samples and data is to provide a
resource that can be repeatedly used for research in
diﬀerent contexts. Governance debates over biobanks
have since then struggled with balancing individual
autonomy and privacy rights with demands for ‘open’
research data.
The protests against the Icelandic biobank project at
the beginning of this millennium allowed critics to suc-
cessfully claim more autonomy and protection for indi-
vidual participants in biobanks (Pa´lsson, 2008). The
Icelandic biobank initiative was mainly criticized for
relying on a presumed consent model (opt-out) and
for the direct involvement of private industry partners
(deCODE Genetics). This highly visible dispute pro-
moted a heightened sensitivity for individual privacy
and informed consent based on an opt-in mode in
European biobanks (Starkbaum, 2018). At the same
time, it led to serious limitation for researchers who
were in need of available data and information.
In response, diﬀerent scholars called for focusing
more strongly on the (possible) research beneﬁts of
biobanks and the risks that aﬀect wider parts of socie-
ties (e.g. genetic discrimination) rather than on individ-
ual data protection. Proponents of this new paradigm
stressed that narrow informed consent models and
unconditional privacy were not compatible with
contemporary data regimes (Knoppers and Chadwick,
2005). Furthermore, biobanks were described as a
‘public good’ in the sense of beneﬁting (future) society,
thus pointing to the collective beneﬁt ﬂowing from
giving broader access to data. This paradigm shift
was labelled as a ‘communitarian turn’, emphasizing
more strongly ideals such as equity and solidarity.
Building biobanks and using them for research was
thus framed less in terms of potential privacy transgres-
sions and more as contributions to the common or
public good. In line with these developments, new
modes of informed consent became dominant in
expert discourses: broad and open consent models
that allow the reuse of data in biobanks based on a
one-time consent (Lunshof et al., 2008). Many larger
biobanks, such as UK Biobank and Biobank Graz, cur-
rently practice such models and link these with sophis-
ticated regulatory and technical measures for protecting
data of unrestricted access.
This dominance of communitarian values was how-
ever opposed by scholars as undermining individual
interests, such as in broad consent models, which
request agreement to unknown future applications
(Caulﬁeld and Kaye, 2009). It was also emphasized
that broad consent mainly authorizes and protects
those who conduct research and does not enlighten
research participants. Some academics therefore advo-
cate for ﬂexible, or dynamic, forms of consent that
increase individual autonomy (Kaye et al., 2015).
These types of consent are designed to give data sub-
jects the opportunity to stay involved – to follow their
data and be able to adjust the form of consent they
initially provided in a context-sensitive manner.
More recent approaches to biobank governance aim
to dissolve these tensions between individual and col-
lective demands in research environments. Following
the challenges of Big Data and precision medicine,
Prainsack and Buyx (2016), for example, draw our
attention to the importance of a solidarity-based
approach to data-related issues that build on notions
of communitarian values while aiming to account also
for the interests of individuals. While this approach
normatively embraces actual practices that constitute
solidarity, and thus addresses foremost collective
demands, it nevertheless emphasizes considering the
needs of individuals by accounting for issues such as
individual privacy demands. Erlich et al. (2014) pro-
pose a trust-based framework and criticize discourses
that frame the value of data as being in opposition to
the participants’ privacy risks. Instead, they aim for
enabling participants and researchers to beneﬁt from
data sharing by shifting the focus from privacy to
trust-enabling notions such as reciprocity and transpar-
ency. These models have, however, not been translated
into widespread practice so far – yet, they build on and
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reinforce the widely established idea of building recip-
rocal relationships with data subjects.
The idea of creating mutual beneﬁts for ‘all’ stake-
holders through reciprocity is not new. Titmuss (1971)
explored regimes of blood transfusions in the 1970s and
concluded that giving blood as an altruistic act creates
reciprocity between strangers, whereas commercial
usage creates non-binding relationships and less reci-
procity. This view has led to debates about whether
commercial and non-commercial practices can be
separated so clearly (Rapport and Maggs, 2002).
Nevertheless, Titmuss’ ideas have been adapted to the
ﬁeld of biotechnology and biobanks: Waldby (2008: 23)
argues that a gift economy, as deﬁned by Titmuss, is
unrealistic as ‘at present the gift system often means
that donors are simply treated as open sources of lucra-
tive biological material’. Other scholars show that some
people indeed frame their donation as a complex give-
and-take relationship across time, more speciﬁcally
‘as a gift towards the welfare state that, in turn, pro-
vides proper treatment’ (Felt et al., 2009: 96). However,
while participants may wish to stay (actively) involved
in research projects, others may prefer to simply donate
a piece of tissue without further active involvement
(Tutton, 2002). All of these scenarios point to the fact
that the situatedness of the act of donation, and a
broader vision of where the donated data and bio-
logical materials might go, matters and needs to be
considered in constructing health-data infrastructures
and providing researchers access to them.
Discussions about reuse of data for research pur-
poses based on one-time consent are thus, in the
wider sense, a debate about the modes of involvement
of participants. While broad consent models are
designed to involve data subjects solely in the process
of data collection and open up further data use for
purposes not imagined at the time of donation,
narrow or dynamic consent models would require the
repeated involvement of those persons who have given
data for research. Recent debates that surrounded the
implementation of the GDPR touch exactly on these
questions.
Opening up a space for negotiating
the GDPR
The policy process that led to the ﬁnal version of the
GDPR allowed various actors to engage in a struggle
over the precise content of this legal key document.
This chapter sketches the major elements of the geneal-
ogy of this process and maps the larger policy network
without referring to internal negotiations of larger
actors such as the EU Parliament.
In reference to the increasing quantities and qualities
of globally available data and the novel possibilities for
retrieving and processing them, approximately a decade
ago multiple voices (e.g. EU oﬃcials and NGOs)
started to raise the issue of the 1995 European Data
Protection Directive (95/46/EC) being outdated. As
certain types of data began to be framed as crucial
resources (e.g. for industry and science), concerns
were expressed that the 1995 Directive might harm
the European economy because it did not oﬀer a clear
EU-wide framework (Ciriani, 2015). Others pointed to
the fact that online data regimes produce novel risks for
EU citizens. International corporations that process
large amounts of data, such as Google and Facebook,
were named in debates on the GDPR and linked to
fears about transnational surveillance or challenges
associated with EU-US data transfer (Krystlik, 2017).
These elements fostered the policy process around data
protection to become quite contested.
In 2012, after lengthy consultations, the EC pro-
posed a comprehensive reform of the current data pro-
tection rules across the EU. The EC explanatory
memorandum to the proposal named legal uncertainty
and public perception of risk as major reasons why a
novel data protection framework was needed:
The current [legislative] framework (...) has not pre-
vented fragmentation in the way personal data protec-
tion is implemented across the Union, legal uncertainty
and a widespread public perception that there are sig-
niﬁcant risks associated notably with online activity.
This is why it is time to build a stronger and more
coherent data protection framework (...) that will
allow the digital economy to develop across the internal
market, put individuals in control of their own data
and reinforce legal and practical certainty for economic
operators and public authorities. (EC, 2012b)
The broader public was thus constructed as con-
cerned (which is quite a general trope in EU policy
documents in regard to providing justiﬁcation for
action) and as a major reason why policymakers had
to act. It was promised that the new GDPR would
provide individuals with control over their personal
data, harmonize EU law, and, in the end, strengthen
the economy.
However, the EU Parliament’s Committee for Civil
Liberties, Justice and Home Aﬀairs (LIBE) disagreed
on some major points of the proposed reform that,
from their perspective, did not provide suﬃcient pro-
tection for European citizens. LIBE stressed the need
for signiﬁcant amendments to the 2012 draft version of
the EC. One major source of conﬂict was the proposal
by the Commission to grant speciﬁc derogations for
data processing to scientiﬁc, statistical, and historical
purposes that would allow science to reuse data for
research based on a one-time informed consent. The
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LIBE Committee opposed these derogations and
pledged for uniﬁed rules for all types of data and appli-
cations. As we will see, the subsequent struggle involved
more than just these two actors.
This oﬃcial EU procedure was accompanied by a
vast amount of input from various actors from ﬁelds
such as industry, human rights, or science with over
3000 amendments from the ﬁrst draft to the ﬁnal
piece. Thus, many observers claim that the GDPR is
one of the most heavily lobbied pieces of EU legislation
in history (International Association of Privacy
Professionals (IAPP), 2015; League of European
Research Universities (LERU), 2016). From the ﬁrst
round of the proposed regulation by the EC in
January 2012, it took until March 2014 to agree on
an initial draft version from the EU Parliament
(Townend, 2016: 137). Initiatives such as LobbyPlag1
or Statewatch2 claimed that actors from industry and
civil society as well as national governments success-
fully inﬂuenced the content of diﬀerent EC and
Parliament draft versions. Topics of debate ranged
from the rights extended to citizens (such as the right
to be forgotten) to speciﬁc derogations for research
purposes.
Stakeholders from (data-dependent ﬁelds of) science
reacted most intensely to the proposals by the LIBE
committee rejecting legal exceptions for data use for
scientiﬁc purposes. As Jan Albrecht, Vice-Chair of the
LIBE Committee, puts it: ‘Processing of sensitive data
for historical, statistical and scientiﬁc research purposes
is not as urgent or compelling as public health or social
protection. Consequently, there is no need to introduce
an exception’ (European Parliament, 2012: 24f). The
Vice-Chair of the LIBE Committee therefore framed
the protection of individual citizens as being more
important than the interests of science, seemingly dis-
connecting research from public health. The proposed
Article 83 of the Parliaments’ legislative resolution of
March 2014 (European Parliament, 2014: 314f) thus
cancelled the EC-suggested exceptions, allowing data
reuse for scientiﬁc purposes based on a one-time
informed consent.
In June 2015, the European Parliament, the EC and
the Council of Europe started the ﬁnal ‘Trialogue’
negotiations. At this time, many central elements were
still up for debate (Hallinan and Friedewald, 2015),
and, as the next section will show, diﬀerent actors con-
tinued to intervene during these ﬁnal negotiations. The
Trialogue reached a compromise in December 2015,
with the ﬁnal text formally approved by the
Parliament and the EC in April 2016. This ultimate
version includes the contested derogations for statis-
tical, historical, and scientiﬁc purposes (e.g. Article
89), allowing individuals to give a one-time consent
for their data to be used for multiple scientiﬁc research
projects across time, condensed by Recital 33 of the
GDPR:
It is often not possible to fully identify the purpose of
personal data processing for scientiﬁc research pur-
poses at the time of data collection. Therefore, data
subjects should be allowed to give their consent to cer-
tain areas of scientiﬁc research . . . (EC, 2016: 6)
The response to the ﬁnal version was comprehensive.
Mass media declared the novel Regulation as ‘ground-
breaking’ and as a ‘milestone’ as it replaced the former
patchwork of national rules with a rule that was legally
binding for all member states (Deutsche Presse
Argentur, 2016; Gibbs, 2016). EU oﬃcials stated in
early 2016 that this Regulation ‘gives citizens back con-
trol over of their personal data’ and that it aims to
‘simplify the regulatory environment’.3 However,
there were also critical voices. Lawyer and privacy
activist Maximilian Schrems, who had gained promin-
ence by criticizing the Safe-Harbour Agreement
between the US and the EU, called the quasi-ﬁnal ver-
sion agreed upon late in 2015 by the Trialogue a com-
plicated, diplomatic text that provides derogations for
individual member states and thus will not guarantee
the often-claimed legal certainty (Wimmer, 2015).
Actors from science widely embraced the ﬁnal ver-
sion of the GDPR most notably because it includes the
repeatedly called-for derogations that allow the reuse of
data for statistical, historical, and scientiﬁc purposes.
Immediately after the Trialogue agreement was
reached, an editorial published by Nature quoted the
senior project manager of BBMRI-ERIC as saying,
‘This is very positive for us – the biggest threats are
over’ (Abbott, 2015: 1), a reaction in line with the
hopes the data-dependent ﬁelds of science had
expressed in the negotiations of the GDPR.
The biobanking agenda for the GDPR
Zooming into the biobank-related actors, we can see
that between 2012 and 2015 they contributed quite
actively to the struggle over the GDPR by organizing
discussion events, having conversations with Members
of the European Parliament (MEPs) and their staﬀ, or
by publishing position papers and open letters includ-
ing quite comparable narratives. Interestingly, this
group comprised not only researchers, science associ-
ations and university representatives but also patient
organizations for rare diseases (e.g. Wellcome Trust
et al., 2014). Considerably increasing the sample size
of biobanks indeed oﬀers novel possibilities for system-
atically studying diseases where data is scarce, which
might explain why these actors co-constitute this issue
alliance.
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The interventions into the debate followed a quite
similar agenda with regard to the topics identiﬁed and
the lines of argument. In doing so, they widely
embraced the EC’s suggestions for the GDPR, in par-
ticular the derogations for data usage for scientiﬁc, his-
torical, and statistical purposes. These actors, linked to
data-dependent ﬁelds of research, were most concerned
about whether the reuse of data for scientiﬁc purposes
was legally possible based on a one-time consent (broad
or blanket consent). In a newsletter published during
the ﬁnal Trialogue, the European infrastructure for bio-
banks, BBMRI-ERIC, called for:
. . . alerting EU policy-makers to the unintended but
harmful eﬀects the GDPR could have on statistical,
scientiﬁc, and historical research and healthcare if
strict restrictions – including a requirement for speciﬁc
consent in science and health research, with only
narrow exceptions – are introduced. (BBMRI-ERIC,
2015a: 5)
A collaboration of patient associations from the ﬁeld of
rare diseases explicitly stressed that ‘it is essential that
Article 83 on processing for historical, statistical and
scientiﬁc research purposes and the associated deroga-
tions that facilitate research are maintained within the
Regulation’ (EURODIS, 2013: 7). Due to the limited
data available for rare diseases, (biobank) research in
this ﬁeld depends even more on the exchange and reuse
of data. Any restrictions on data usage would, in their
view, result in delays to the improvement of health care
and represent discrimination against patients with rare
diseases.
Various actors framed data as a vital resource for
science and the Parliament’s rejection of data reuse for
scientiﬁc purposes as a direct threat to scientiﬁc
research and advances in the ﬁeld of medicine. The
Karolinska Institute, one of the world’s most renowned
medical universities, together with Stockholms Lans
Landsting published an open letter that called data cru-
cial for improving public health and a vital resource for
research that beneﬁts society and saves patients’ lives
(Karolinska Institute and Stockholms Lans Landsting,
2014). In this line of argument, as in many others, the
reuse of data is explicitly seen as a central precondition
for medical progress and public beneﬁts. The latter
were not solely seen as improvements in health care
but also as links to economic aspects of society.
The Wellcome Trust, a global charitable foundation
that supports research, claimed in an open letter with
others that the proposed legislation of the Parliament
‘jeopardize[s] millions of Euros of investment in scien-
tiﬁc infrastructure, including cancer registries, cohort
studies and biobanks’ (Wellcome Trust et al., 2014:
1). In line with this argument, Science Europe, a
Brussels-based association of 51 European national
research funding and performing organizations with
the declared aim of promoting the collective interests
of its members, stressed in their position paper the
importance of keeping open the possibilities of sharing
and processing data for the sake of societal beneﬁts:
Scientiﬁc researchers across Europe, in particular in
the social sciences, medical sciences, life sciences
and humanities, produce high-impact, world-leading
research results with huge societal beneﬁt, which heav-
ily depend on sharing and processing of datasets which
include personal data. (Science Europe, 2013: 3)
A position paper by BBMRI-ERIC, which involved the
input of 18 National Nodes of BBMRI-ERIC and the
ethical, legal, and societal experts of the internal
Common Service ELSI, warned that the Parliament’s
versions of the Regulation ‘could seriously hamper pan-
European research’ (BBMRI-ERIC, 2015b: 3) by intro-
ducing ‘overly speciﬁc consent with only a narrow
exception in science and health research’ (BBMRI-
ERIC, 2015b: 5). BBMRI-ERIC also emphasized that
biomedical research has a ‘substantive public interest’
(BBMRI-ERIC, 2015b: 3) because it furthers know-
ledge about health and helps to develop new treatments
and therapies. It thereby underlined the importance of
access to high-quality samples and (Big) Data that
could be shared across Europe. The biobank infrastruc-
ture thus named the possible negative impacts for
European research:
In order to achieve reliable and reproducible results,
health research depends on high quality samples and
Big Data, which will often need to be shared across
borders in order to achieve the best. The GDPR
could greatly ease transnational health research and
cross-border exchange of data to further biomedical
innovation for the beneﬁt and wellbeing for European
citizens and patients. At the same time, wrongly aimed
provisions could seriously hamper pan-European
research as well. (BBMRI-ERIC, 2015b: 5)
When the modes of informed consent were addressed,
this topic was entangled with the interests of patients
and wider publics in a variety of ways. Science Europe
(2013: 5) explicitly named broad consent as the stand-
ard mode in cohort studies and biobanks, which min-
imizes the burden on participants because there is no
need to re-consent for each new study in which their
data are used. BBMRI-ERIC followed a comparable
argument by focusing on the interests and rights of
patients. Their position paper on the GDPR framed
the inclusion of data and biomaterials in biobanks
and related research as a right of patients, even if the
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exact future research objectives cannot be deﬁned yet
(BBMRI-ERIC and ISC, 2015: 3), while it explicitly
framed the need to re-consent as a burden on patients
(BBMRI-ERIC, 2015b: 6). The respective BBMRI-
ERIC recommendations on the GDPR – based on a
discussion event in Brussels with scientists, MEPs,
and other stakeholders (‘2015 Day of Action on Data
for Health and Science’) – followed a similar path in
stressing ‘the right to donate’:
Many patient groups say that they do not want to re-
consent to each new study, having allowed the usage of
their data for scientiﬁc purposes for altruistic reasons,
especially those with cancer or chronic diseases.
Consequently, patients should have the option to
donate their data and biomaterials to biobanks and
research entities without restricting their consent to a
speciﬁc study. This option would allow their data to be
used for biomedical research for the beneﬁt of the
donors as well as future patients. Many future research
purposes are impossible to predict at the time of data
collection due to constant developments and progress
in science. In addition, continuous re-consent is bur-
densome for many patients, not least because it reminds
patients of their condition. ‘‘ – the quotation would
remain the same (BBMRI ERIC 2015: 2).
Protection of data and data privacy are addressed in
the documents by research-related stakeholders; how-
ever, they are not as detailed as one might have
expected given that ‘data protection’ is at the core of
this new legislation. Beyond references to the fact that
privacy instruments are already in place (LERU, 2014),
issues of data protection and privacy were typically not
addressed in their own right but regarded as an issue
already cared for. Rather, policy makers were called to
strike a balance between privacy risks of data donors
on the one hand and collective research and health
beneﬁts on the other. This argument can be clearly
observed in the statement of EURODIS, the
European association for rare diseases: ‘It is of funda-
mental importance to balance privacy rights with the
right to protection of health and to bear in mind the
ethical value of solidarity in sharing data to provide
better health to others’ (EURODIS, 2013: 7). Here,
the introduction of ‘the ethical value of solidarity’
should be highlighted, emphasizing that providing
data for research could also be framed as an act of
solidarity and thus as contributing to a wider system
of shared long-term beneﬁts for treating rare diseases.
Another balancing argument was that data are a
resource that could likely ‘go to waste’ if they cannot
be used for research (LERU, 2014: 1), which can be
seen as referring to the trope of responsible use of
resources. The metaphor of ‘the balance’ was also
explicitly used by the Wellcome Trust and the co-sign-
ing institutions and researchers, alerting readers to not
underestimate the beneﬁts associated with data sharing:
‘We believe it is vital that regulation strikes a balance to
protect the interests of individuals while enabling
research that beneﬁts all society’ (Wellcome Trust
et al., 2014: 1). Science Europe also aligned with this
argument:
Science Europe believes that the new Regulation should
reconcile the protection of individual rights to privacy
with the safe processing of personal data for scientiﬁc
purposes. A failure to strike the right balance would
have major implications for a large number of diﬀerent
scientiﬁc research activities across Europe and would
signiﬁcantly reduce capacity for innovation and com-
petitiveness. (Science Europe, 2013: 2)
Finally, stakeholders associated with biobanks warned
that the rejection of derogations for data reuse for
science would seriously threaten the very idea of data-
driven research:
It is therefore alarming that the proposed amendments
would make much of the research involving personal
data at best unworkable (by severely hampering
options for collecting, using and sharing data
from registries and biobanks) and at worst illegal.
(Karolinska Institute and Stockholms Lans
Landsting, 2014: 1)
This last quotation reveals how an all-too-restrictive
data protection was framed as a threat to research
more generally and how the struggle over the GDPR
connected to larger questions about data, science and
society.
Discussion
This paper focuses the struggle over data reuse for
research purposes in the context of the GDPR. We use
this moment of controversy to better understand the
reordering of the research landscape due to data inten-
sive approaches, while also needing to strive for an ade-
quate protection of both data and data subjects. To do
so we start by exploring biobank-governance debates
more generally and subsequently analyse the interven-
tions of actors associated with this ﬁeld in the negoti-
ations between 2012 and 2015 that led to the
ﬁnal GDPR. We observe the eﬀorts to perform a para-
digmatic shift of the discourse around the GDPR-imple-
mentation away from ‘protecting data’ as key concern to
‘protecting health’ of individuals and societies at large.
We can see this negotiation not only as an engage-
ment in discussing the GDPR, but also as a moment
8 Big Data & Society
when the needs of contemporary ways of doing data-
intensive biomedical research were spelled out in the
policy arena. While science has always relied on
research data, the increasing possibilities (and prom-
ises) to create and make use of Big Data not only
opens up new ﬁelds of research but also (potentially)
enables ground-breaking analytical possibilities in ﬁelds
such as disease prediction or personalized health. Some
authors thus highlight that the epistemologies of science
are shifting towards a type of science that is much more
closely tied to (digital) data analytics. Kitchin (2014: 1),
for example, calls ‘Big Data and new data analytics
(. . .) disruptive innovations which are reconﬁguring in
many instances how research is conducted’. Biobanks
and the European biobank infrastructure BBMRI-
ERIC can be considered a manifestation of this new
type of science.
The analysed interventions of actors associated with
biobanks, reveal a clearly shared systemic interest in data
reuse. This is not astonishing as with the increasing eﬀorts
of pooling data, reuse has become a foundational prin-
ciple of data infrastructures such as biobanks. Through
their common narratives and arguments, these actors
thus emphasized the values and beneﬁts of data-driven
research. Data protection issues were then either not
addressed explicitly or they were balanced against the
advantages this kind of research would bring for science
and societies. Practices of meeting withMEPs, organizing
workshops, and writing position papers and open letters
constituted the shared repertoire of arenas in which per-
suasion had to happen. While there was no ‘oﬃcial’ bond
that connected the research-related actors we encoun-
tered, the various contributions followed a similar
agenda and more or less aligned in the argumentative
repertoires they used. Together, this allowed the forma-
tion of a quite-powerful discourse coalition (Hajer, 2009)
that gained visibility in this larger struggle over the
GDPR through sharing argumentative resources.
Building issue-based tacit alliances had the advantage
that no overall agreement needed to be reached regarding
other research related policies among these actors. In
creating a shared story line about the beneﬁts of data-
driven biomedical research, they challenged other narra-
tives across the discursive space.
As the ﬁnal version of the GDPR contains the
called-for derogations for reuse of (personal) data for
research, statistical and historical purposes based on a
one-time consent (e.g. Recital 33), it could be concluded
that this coalition has achieved its mission. However,
there seems to be room for interpretation: we can today
observe diverging readings of the possibilities for data
reuse. The Article 29 Data Protection Working Party
(2018: 28), for example, recently issued a widely cited
document that clearly emphasizes the importance for
a well-described purpose of data use in informed
consent: ‘When regarded as a whole, the GDPR
cannot be interpreted to allow for a controller to navi-
gate around the key principle of specifying purposes for
which consent of the data subject is asked’. Actors asso-
ciated to biobanks and its European infrastructure,
such as Holub et al. (2018), claim, on the contrary, to
strengthen even further the possibilities for eﬀective
reuse of biological material and data. The ways in
which the GDPR will be practiced over the years to
come is thus not a closed issue and will demand inter-
pretative work.
This debate over the interpretation of the data reuse
regulation actually links to a pre-existing struggle
already observed in biobank governance debates
around the turn of the Millennium. While the GDPR
has provided some legal clarity, it has not solved nor
addressed suﬃciently the key problem of informed con-
sent: that it often fails to properly engage with people
involved in data transfers, which applies to both
narrow and broad forms (Caulﬁeld and Kaye, 2009).
Our data indicates that the exchange of information
with data subjects was not a key concern in the argu-
ments of biobank related actors that rather highlighted
the (potential) beneﬁts of biomedical research. The
involvement of data from patients and other individ-
uals is accordingly mainly framed as ‘donation’
(BBMRI-ERIC and ISC, 2015: 2), which implies no
further connection of data subjects to the research
after data have been provided. Data management and
data privacy measures are framed as a task of scientists
and biobankers and not as a process that others should
be involved in over time.
The discourse coalition also entailed a speciﬁc con-
struction of patients. They are depicted as wanting
‘their’ data to be used while restrictions on data
reuse, such as re-consenting in narrow informed con-
sent models, are framed as a burden for them rather
than as a protective or empowering element. This line
of argument stands in tension with the simultaneously
made arguments that build on the reciprocity between
research and those who provide data (Kaye et al., 2015;
Titmuss, 1971) or that underline the importance to sup-
plement informed consent models with attempts for
deliberation, participation and representation (Gould,
2019). These arguments are in line with the currently
widespread claim for more inclusive forms of research,
manifested in frames such as Responsible Research and
Innovation (Braun and Griessler, 2018; Felt, 2018).
Indeed, in our analysis, we did only examine the
voices of rather institutionalized actors as spokesper-
sons for larger sets of people – be they aﬀected by
rare diseases, biobankers, or science policy actors.
While these spokespersons and their alliances were
surely the most powerful agents in this negotiation pro-
cess, we are reminded by Callon et al. (2009) that
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speaking in the name of people means silencing those
represented, not allowing to voicing and addressing the
diﬀerences in opinion.
The observed formation of a discourse coalition, its
focus on potential beneﬁts and the ways how patients
and citizens are imagined, can be understood as a rea-
sonable ‘reaction’ to potential restrictions for data
reuse, as the very idea of biobanking is conceptualized
around long-term use of readily prepared data. Legal
and regulatory measures are potentially associated with
higher drop-out quotes and limited data access and
might thus challenge the potential ‘beneﬁt and well-
being for European citizens and patients’ (BBMRI-
ERIC, 2015b: 5). In this line, these debates do not
emphasize the exchange of information with patients
and citizens, although there is a large body of literature
emphasizing the importance of this (Starkbaum, 2018).
Also, the very ontology of biobanks, and the vast
amount of resources they demand (Caulﬁeld, 2018), is
not questioned in these debates, as biobanks align with
the hegemonic trend for Big Data science and the bene-
ﬁts presumably outscore potential risks. While the
GDPR seems to have brought a satisfactory closure
to the threats perceived to data-intensive biomedical
research, open issues remain. Current developments
related to Big Data reconﬁgure the relationships of
power between science – in our case bio(medical)sci-
ences – and society (Jasanoﬀ, 2017). Indeed, in order
to make biobanks sustainable on the long-term, gov-
ernance modes need not solely to comply to the GDPR,
but to proactively re-imagine its relation to citizens and
data subjects in order to account for the various ways
that science gets entangled with society.
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